Neuroimaging of Primary Progressive Aphasia Variants

A. Wasim, J.E. McConathy, M. Natelson Love, and E.H. Middlebrooks

View Article on Neurographics Website

Date of Activity Release: Feb. 1, 2018
Date of Activity Expiration: Feb. 1, 2021

Target Audience:
Intended for neuroradiologists and neuroradiology trainees with varying degrees of experience.

Learning Objective:
Describe the clinical features and imaging findings that distinguish the variants of primary progressive aphasia.

Primary progressive aphasia is a neurodegenerative syndrome, with the common feature being aphasia in the absence of marked impairment in other cognitive and behavioral domains. Three primary subtypes have been described: 1) nonfluent or agrammatic primary progressive aphasia, 2) semantic primary progressive aphasia, and 3) logopenic primary progressive aphasia. Although sharing the same primary progressive aphasia designation, these variants show very diverse clinical phenotypes, molecular pathologies, and neuroimaging findings. This review presented current knowledge of clinical phenotypes, molecular pathologies, and multimodal neuroimaging findings, including MR imaging, FDG-PET, amyloid PET, tau PET, and DTI. With increased awareness of the spectrum of neuroimaging abnormalities, the neuroradiologist can potentially add valuable information in correctly categorizing these patients and their underlying pathologies.

Commercial Support
No commercial support was received for this activity.

Credit Designation Statement

The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation:
Each participant will review the corresponding Neurographics article located at Upon completion, each physician will complete and pass a post-test with a score of at least 80% to receive a CME certificate.

All individuals in control of content have disclosed the following relevant financial relationships. All of these relationships were treated as a conflict of interest, and have been resolved (C7 SCS 6.1-6.2, 6.5)

Authors have no relevant financial relationships.





Barton Branstetter 

Editor in Chief

None, N/A

Adam Flanders

Deputy Editor

Royalties, Lippincott Williams and Wilkins

Robert Quencer 

Consulting Editor

None, N/A

Mark Mullins

Associate Editor

Non-remunerative position, AUR6

Meng Law

Associate Editor

Stockholder, Clinical Imaging

Edward Escott

Associate Editor

Grant, Atherysys, Inc.; Royalties, Thieme Medical Publishers

Scott Faro

Associate Editor

None, N/A

Tina Young Poussaint

Associate Editor

None, N/A

Dheeraj Ghandi

Associate Editor

Grant, Arstasis, Axera Inc.; Consultant, Covidien, EV3

Contact Information:
If you have questions regarding this enduring material activity, please contact us at

Privacy Policy and Confidentiality Policy:
The ASNR does not share your personal information provided to this site with any third party, except where required by CME governing bodies for verification of CME activities. Your email address will only be used to contact you in relation to your activities on the website, except where you have given ASNR permission to contact you with additional information. ASNR adheres to the same policy for members as nonmembers, except that: ASNR member mailing address information may be shared with providers of accredited CME activities.

Copyright © American Society of Neuroradiology, 2011-2018